These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18091609)

  • 1. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients.
    Horberg MA; Silverberg MJ; Hurley LB; Towner WJ; Klein DB; Bersoff-Matcha S; Weinberg WG; Antoniskis D; Mogyoros M; Dodge WT; Dobrinich R; Quesenberry CP; Kovach DA
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):384-90. PubMed ID: 18091609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.
    Chung MH; Richardson BA; Tapia K; Benki-Nugent S; Kiarie JN; Simoni JM; Overbaugh J; Attwa M; John-Stewart GC
    PLoS Med; 2011 Mar; 8(3):e1000422. PubMed ID: 21390262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.
    Li X; Margolick JB; Conover CS; Badri S; Riddler SA; Witt MD; Jacobson LP
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):320-8. PubMed ID: 15735452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
    Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients.
    Dalessandro M; Conti CM; Gambi F; Falasca K; Doyle R; Conti P; Caciagli F; Fulcheri M; Vecchiet J
    J Clin Psychopharmacol; 2007 Feb; 27(1):58-61. PubMed ID: 17224714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse and resilience in relation to HAART medication adherence and HIV viral load among women with HIV in the United States.
    Dale S; Cohen M; Weber K; Cruise R; Kelso G; Brody L
    AIDS Patient Care STDS; 2014 Mar; 28(3):136-43. PubMed ID: 24568654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
    Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of adherence on CD4 cell count responses among HIV-infected patients.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2004 Mar; 35(3):261-8. PubMed ID: 15076240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR; Chaisson RE; Moore RD
    AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
    Nieuwkerk PT; Sprangers MA; Burger DM; Hoetelmans RM; Hugen PW; Danner SA; van Der Ende ME; Schneider MM; Schrey G; Meenhorst PL; Sprenger HG; Kauffmann RH; Jambroes M; Chesney MA; de Wolf F; Lange JM;
    Arch Intern Med; 2001 Sep; 161(16):1962-8. PubMed ID: 11525698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An investigation of the possible interaction between the use of Vitamin C and highly active antiretroviral therapy (HAART) adherence and effectiveness in treated HIV+ women.
    Merenstein D; Wang C; Gandhi M; Robison E; Levine AM; Schwartz RM; Weber KM; Liu C
    Complement Ther Med; 2012 Aug; 20(4):222-7. PubMed ID: 22579434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.